Transforming medicine and changing lives
April 29, 2021
Selecta Biosciences and AskBio Announce Updates to Methylmalonic Acidemia (MMA-101) ProgramMethylmalonic Acidemia (MMA) program to become wholly-owned by Selecta. Selecta to postpone IND submission until at least the fourth quarter of 2021. Empty capsid (SEL-399) study remains on track ...read the news
We are on a never-ending quest to advance genetic technology
and life-saving AAV gene therapy
In 1984, Dr. Jude Samulski, one of AskBio’s visionary founders, asked if a virus could be used to erase genetic disease. Discovering the answer cleared the path for historic advances in genetic medicine, and AskBio is leading the way.
Revolutionizing gene therapy
Cures for life-altering diseases depend on new technology to lower the cost of treatment and increase supply for every patient who needs it.
Changing lives
Our clinical pipeline is the direct result of listening to patients, their families, their care teams and disease-advocacy organizations.
Putting patient care first
The voices of patients drive everything we do. They propel our research and the urgent need to find cures.
Work with us
Advancing research
Today’s genetic discoveries are some of the most awe-inspiring advances in medical history. We welcome collaboration with innovative minds in genetic R&D.
Building careers
Help transform the face of healthcare with life-changing gene therapy. Every life enriched by our scientific advancements is a result of someone like you.
